CA1148799A - Dialysis process for the production of bilayer vesicles - Google Patents
Dialysis process for the production of bilayer vesiclesInfo
- Publication number
- CA1148799A CA1148799A CA000368757A CA368757A CA1148799A CA 1148799 A CA1148799 A CA 1148799A CA 000368757 A CA000368757 A CA 000368757A CA 368757 A CA368757 A CA 368757A CA 1148799 A CA1148799 A CA 1148799A
- Authority
- CA
- Canada
- Prior art keywords
- dialysis liquid
- bilayer
- membrane
- dialysis
- detergent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Manufacturing Of Micro-Capsules (AREA)
- Medicinal Preparation (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
A process is provided herein for producing bilayer vesicles from a colloidal solution comprising mixed micelles of a bilayer-forming sub-stance and a detergent. The process comprises removing the detergent from the micelle-containing colloidal solution by means of flow-through dialysis so that the colloidal solution is dialyzed against a dialysis liquid in a chamber whose walls are at least partially formed by a semi-permeable membrane. In such dialysis, the dialysis liquid is moved along the outer side of the semi-permeable membrane at a velocity such that the detergent concentration in the dialysis liquid, on at least 90% of the active sur-face of the membrane, is at most 10% of the detergent concentration in the micelle solution in contact with the other side of the membrane. In addition, a homogeneous detergent concentration is maintained in the micelle solution by the movement of the micelle solution. The bilayer vesicles produced thereby do not suffer from the undesired properties of inclusion of organic solvents, degradation of the bilayer forming substance, the formation of multi-lamellar structures and the formation of nonhomogeneous sized vesicles.
A process is provided herein for producing bilayer vesicles from a colloidal solution comprising mixed micelles of a bilayer-forming sub-stance and a detergent. The process comprises removing the detergent from the micelle-containing colloidal solution by means of flow-through dialysis so that the colloidal solution is dialyzed against a dialysis liquid in a chamber whose walls are at least partially formed by a semi-permeable membrane. In such dialysis, the dialysis liquid is moved along the outer side of the semi-permeable membrane at a velocity such that the detergent concentration in the dialysis liquid, on at least 90% of the active sur-face of the membrane, is at most 10% of the detergent concentration in the micelle solution in contact with the other side of the membrane. In addition, a homogeneous detergent concentration is maintained in the micelle solution by the movement of the micelle solution. The bilayer vesicles produced thereby do not suffer from the undesired properties of inclusion of organic solvents, degradation of the bilayer forming substance, the formation of multi-lamellar structures and the formation of nonhomogeneous sized vesicles.
Description
7~9 The present invention relates to a process for producing bilayer vesicles by forming mixed micelles in a colloidal solution from a bilayer-forming substance and a deter~ent, and removing the detergent by means of flow-through dialysis.
Substances which are capable of forming bilayers (i.e., double layers) in the aqueous phase are known, for example phospholipicls, such as lecithin. These bilayers are frequently in the shape of small hollow spheres which are hereinafter referred to as bilayer vesicles.
Known processes for producing bilayer vesicles, such as subjecting bilayer-forming substances to ultra-sound, injecting bilayer-forming substances dissolved in organic solvents into an aqueous medium, removing detergents from micelle solutions (i.e., solutions of mixed micelles of bilayer-forming substance and detersent) by means of gel chromatography, and conventional dialysis [compare Biochim. Biophys. Acta 457, 259-302 (1976), CRC
Critical Reviews in Toxicology 6, 25-79 (1978)], produce bilayer vesicles with undesired properties. The main disadvantages of such processes are characterized by the inclusion of organic solvents in the bilayer vesicles, the degradation of the bilayer-forming substance, the ~1~87<~9 formation of multi-lamellar structures and, in particular, the formation of vesicles which are nonhomogeneous in size (20 to 200 nm in diameter).
Furthermore, undesired dilution effects can oecur and these necessitate a subsequent concentration process. If bilayer vesicles are employed as medicament carriers andtor as pharmaceutical preparations, the resultant plasma clearance and distribution in the organs are determined above all by the homogeneity of the vesicles and the vesicle size. Multi-lamellar heterogeneous structures are rapidly absorbed, in particular, by the spleen and the liver and are no longer available to the organism as a pharmodynami-eally aetive substance [Biochim. Biophys. Res. Comm. 63 651-658 L1975)].
The Extent and course of this process, and the interaction of the vesicles at the cellular level, ean be controlled by selection of suitable lipid composition and morphology (size) of the vesicles [Science, Volume 205, 1,142 - 1,144 (1979); Biochim. Biophys. Acta, Volume 541, 321-333 (1979)].
Accordingly, it is an object of one broad aspect of this invention to provide a process which overcomes these disadvantages and by which bi-layer vesicles of a homogeneous size can be produced.
According to one broad aspect of this invention a process is provided for producing bilayer vesicles from a colloidal solution com-prising mixed micelles of a bilayer-forming substance and a detergent, the process comprising removing the detergent from the micelle-containing colloidal solution by means of flow-through dialysis, whereby the colloidal solution is dialyzed against a dialysis liquid in a chamber formed at least partially by a semi-permeable membrane, wherein the dialysis liquid is moved along one side of a semi-permeable membrane at a velocity such that the detergent concentration in the dialysis liquid, on at least 90~ of the active surface of the membrane, is at most 10% of the detergent concentra-tion in the micelle solution in contact with the other side of the membrane, ; .
~i, 37~9 and wherein a homogeneous detergent concentration is maintained in the micelle solution by movement of the latter.
By a variant thereof, the velocity of the dialysis liquid is chosen such that the detergent concentration in the dialysis liquid is at most 2~ of the detergent concentration in the micelle solution.
By another variant thereof, the velocity of the dialysis liquid is chosen such that the detergent concentration in the dialysis liquid is at most 1% of the detergent concentration in the micelle solution.
By a further variant thereof, the dialysis liquid is carried along the membrane in at least one channel which is in contact with the outer side of the membrane.
By a variation thereof, the channel may be a meandering channel or a spiral channel.
By another variant, the dialysis liquid is moved along the mem-brane in laminar flow.
By a further variant, the colloidal solution of the mixed micelles further comprises at least one of the following additives: an electrolyte, a sorption promoter, an auxiliary, a peptide, a protein, a nucleic acid, a lipid, an antigen, an antibody or a biologically or pharmacodynamically active material.
By another aspect of this invention a novel bilayer vesicle is produced by the process described above.
By one variant thereof, the bilayer vesicle comprise a biologically or pharmacodynamically active material.
In the accompanying drawings, reference characters designate the same or similar parts throughout the several views, Figure 1 shows a cross section through a dialysis cell and Figure
Substances which are capable of forming bilayers (i.e., double layers) in the aqueous phase are known, for example phospholipicls, such as lecithin. These bilayers are frequently in the shape of small hollow spheres which are hereinafter referred to as bilayer vesicles.
Known processes for producing bilayer vesicles, such as subjecting bilayer-forming substances to ultra-sound, injecting bilayer-forming substances dissolved in organic solvents into an aqueous medium, removing detergents from micelle solutions (i.e., solutions of mixed micelles of bilayer-forming substance and detersent) by means of gel chromatography, and conventional dialysis [compare Biochim. Biophys. Acta 457, 259-302 (1976), CRC
Critical Reviews in Toxicology 6, 25-79 (1978)], produce bilayer vesicles with undesired properties. The main disadvantages of such processes are characterized by the inclusion of organic solvents in the bilayer vesicles, the degradation of the bilayer-forming substance, the ~1~87<~9 formation of multi-lamellar structures and, in particular, the formation of vesicles which are nonhomogeneous in size (20 to 200 nm in diameter).
Furthermore, undesired dilution effects can oecur and these necessitate a subsequent concentration process. If bilayer vesicles are employed as medicament carriers andtor as pharmaceutical preparations, the resultant plasma clearance and distribution in the organs are determined above all by the homogeneity of the vesicles and the vesicle size. Multi-lamellar heterogeneous structures are rapidly absorbed, in particular, by the spleen and the liver and are no longer available to the organism as a pharmodynami-eally aetive substance [Biochim. Biophys. Res. Comm. 63 651-658 L1975)].
The Extent and course of this process, and the interaction of the vesicles at the cellular level, ean be controlled by selection of suitable lipid composition and morphology (size) of the vesicles [Science, Volume 205, 1,142 - 1,144 (1979); Biochim. Biophys. Acta, Volume 541, 321-333 (1979)].
Accordingly, it is an object of one broad aspect of this invention to provide a process which overcomes these disadvantages and by which bi-layer vesicles of a homogeneous size can be produced.
According to one broad aspect of this invention a process is provided for producing bilayer vesicles from a colloidal solution com-prising mixed micelles of a bilayer-forming substance and a detergent, the process comprising removing the detergent from the micelle-containing colloidal solution by means of flow-through dialysis, whereby the colloidal solution is dialyzed against a dialysis liquid in a chamber formed at least partially by a semi-permeable membrane, wherein the dialysis liquid is moved along one side of a semi-permeable membrane at a velocity such that the detergent concentration in the dialysis liquid, on at least 90~ of the active surface of the membrane, is at most 10% of the detergent concentra-tion in the micelle solution in contact with the other side of the membrane, ; .
~i, 37~9 and wherein a homogeneous detergent concentration is maintained in the micelle solution by movement of the latter.
By a variant thereof, the velocity of the dialysis liquid is chosen such that the detergent concentration in the dialysis liquid is at most 2~ of the detergent concentration in the micelle solution.
By another variant thereof, the velocity of the dialysis liquid is chosen such that the detergent concentration in the dialysis liquid is at most 1% of the detergent concentration in the micelle solution.
By a further variant thereof, the dialysis liquid is carried along the membrane in at least one channel which is in contact with the outer side of the membrane.
By a variation thereof, the channel may be a meandering channel or a spiral channel.
By another variant, the dialysis liquid is moved along the mem-brane in laminar flow.
By a further variant, the colloidal solution of the mixed micelles further comprises at least one of the following additives: an electrolyte, a sorption promoter, an auxiliary, a peptide, a protein, a nucleic acid, a lipid, an antigen, an antibody or a biologically or pharmacodynamically active material.
By another aspect of this invention a novel bilayer vesicle is produced by the process described above.
By one variant thereof, the bilayer vesicle comprise a biologically or pharmacodynamically active material.
In the accompanying drawings, reference characters designate the same or similar parts throughout the several views, Figure 1 shows a cross section through a dialysis cell and Figure
2 shows a front view of a side-wall element of the cell of Figure 1.
- 3 -7~39 The removal of detergents from micelle solutions by means of known dialysis processes (e.g., by equilibrium - 3 a -dialysis, for example, by the dialysis bag method) leads to nonhomogeneous bilayer vesicles of various sizes and to multi-lamellar structures. It has been established that this is derived from the uncontrolled dialysis kinetics of the detergent. These nonuniform dialysis kinetics result from the fact that concentration gradients, which are constantly changing and, hence, cannot be controlled, build up both in the material to be dialyzed (the micelle solution) and also in the dialysate. This results in a constan~ly changing dialy-sis rate of the detergent, which can hardly be influenced, and which continuously changes the size distribution of the mixed micelles. The complete removal of the detergent from the micelle solution takes a very long time and exacerbates the above-mentioned disadvantages of the process.
To avoid uncontrollable changes in the concen-tration gradient transverse to the semi-permeable membrane, the process of this invetnion comprises moving the dialysis liquid, on at least one side of a semi-permeable membrane, at a velocity such that the detergent concentration in the dialysis liquid, on virtually the whole of the active surface of the membrane, in any case on at least 90% of this surface, is at most 10% of the detergent concentration in the micelle solution in contact with the other side of the membrane, and maintaining a homogeneous detergent concentration ~1~8~9 in the micelle solution by the movement, e.g., stirring, of the latter.
In this way, by keeping the detergent concentration in the dialysis liquid which is in contact with the membrane as low as possible at all points, preferably below about 2%, for example at about 1% or less, relative to the detergent concentration in the micelle solution, it is possible to ensure that, at all points on the active membrane surface, virtually identical concentration gradients are formed normal to the membrane surface. Homogeneous bilayer vesicles of a defined size, which can be used as carriers for biologically and pharmacodynamically active substances and/or can be employed as pharmaceutical preparations, are thereby obtained after a relatively short dialysis time.
Preferably, the dialysis liquid is carried past the semi-permeable membrane, with a constant flow velocity in laminar flow, in such a way that a linear concentration ~radient of the detergent is formed from the entry of the dialysis liquid into the flow-through compartment up to its discharge as dialysate. In flow-through dialysis of this type, the intermediates resulting from the formation of the bilayer vesicles are already in themselves homogeneous and defined.
The desired homogeneous bilayer vesicles of defined size are formed from these intermediates after removal of the detergent. The bilayer vesicle size can be con-trolled and selected conventionally byselection of the molar ratio of bilayer-forming substances/detergent in the initially formed colloidal solution, or by suitable choice of the detergent, or by choice of the dialysis kinetics of the detergent. Such dialysis kinetics, (i.e., dialysis rate) in turn depend, in a known manner, on the temperature, the ratio of membrane surface area/solution volume, the type of membrane (thickness, pore size), the concentration and the physical and chemical properties of the substances to be dialyzed. (See, e.g., a) "Membrane Separation Processes", P. Meares ed., chapter 1 and 2, p. 1-79, Elsevier Scientific Publ. Comp., New York (1979); b) Biochemistry 18, 4173-4176 10 (1976).
A laminar flow of the dialysis liquid over the membrane surface has the advantage that the flow velocity can be kept approximately the same over the whole surface, and this is important since the flow velocity should be as high as possible, interalia because of the desired low deter-gent concentration in the dialysis liquid, but a certain maximum, beyond which the molecular film on the membrane would be destroyed, of course, should not be exceeded. Preferably, the flow velocity of the dialysis li-quid in the immediate vicinity of the membrane surface, at as many points as possible, is in the region of 0.2 - 6 m~minute, advantageously in the region of 1-3 m/minute.
The preferred laminar flow can be ensured, for example, by arranging, in the flow-through compartment, ., ~148799 guide elements which are in contact with the membrane and which carry the dialysis liquid along the surface of the membrane in laminar flow. For example, the dialysis liquid can be carried over the surface of the membrane in a meandering or spiral channel in an element which is in contact with the membrane. Alternatively, it is also possible simply to construct the flow-through compartment with very low thickness (measured normal to the membrane), preferably a thickness of less than 1 mm. If this thickness is not more than about 2 mm and the dialysis liquid is introduced into the flow-through compartment, distributed over the width of the latter, an approximately laminar flow is likewise achieved at virtually all points.
The movement of the micelle solution in contact with the other side of-the semi-permeable membrane, which movement is employed to rnaintain a homogeneous detergent concentration in the micelle solution, can be achieved, for example, by stirring with a mechanical stirring member (for example a magnetic stirring rod), or by forcing an inert gas into the chamber containing the micelle solution, or by moving the whole dialysis device to and fro (tilting movements) with this chamber.
The drawing shows a dialysis device with which anembodiment of the process of this invention can be carried out.
In the dialysis cell of Figures 1 and 2, two semi-permeable membranes 1 are arranged between the ring 2 ~8799 and, in each case, a side-wall element 3. A colloidal solution of mixed micelles is brought (e.g., through closable orifices in ring 2, which are not shown) into the interior space 4 between the two membranes 1.
The semi-permeable membranes must be impermeable to the bilayer-forming substances and to the aggregates or associates (e.g., the micelles, unilamellar or multi-lamellar vesicles) formed therefrom, but permeable to solvents and to auxiliaries and active substances dis-solved therein. The following are particularly suitable as components of the membranes: cellulose, hydrated cellulose, regenerated cellulose (e.g., cellophane) as well as cellùlose derivatives such as acetyl cellulose, furthermore polyamides, polyalkylenes such as polyethy-lene or polypropylene, polyesters, polyvinyl chloride,polytetrafluoroethylene, polycarbonates, etc.
The preferred membrane thickness is about 5 to about 20~m.
The mixed micelles are produced from a deter-gent (solubilizer) and bilayer-forming substances.
Suitable micelle-forming solubilizers are nonionic, anionic, cationic or amphoteric detergents.
The following are particularly suitable as detergents: cholic acid, their salts and derivatives such as desoxycholic acid, taurocholic acid, cheno-desoxycholic acid, lithocholic acid, glycocholic acid and their salts, preferably their sodium salts; glyco-sides, above all monomeric or oligomeric sugar derivatives 9s' with lipophilic sidechain,e.g., 1-O~n-hexyl-~-D-glucopyranoside, l-O-n-heptyl-~-D-glucopyranoside or l-O-n-octyl-~-D-glucopyranoside.
Among the anionic solubilizers, there are suited in particular the Na and K salts of fatty acids of, preferably, 8 to 24 C atoms, amine soaps (e.g., tri-ethanolamine stearate), salts of sulfuric and sulfonic acid esters of higher fatty alcohols such as sodium lauryl sulfate, docusate sodium salt or sodium lauryl sulfonate; among the cationic, quaternary ammonium compounds. Suitable nonionic solubilizers include, e.g., partial fatty acid esters of polyvalent alcohols such as glycerol monostearate, pentaerythritol mono-stearate; partial fatty acid esters of sorbitan (e.g., Span ~ , Crill ~ ) and of polyoxyethylene sorbitan (e.g., Tween ~ ), reaction products of castor oil or hydrogenated castor oil with ethylene oxide (e.g., Cremophor ~ EL), ethoxylated saturated fatty alcohols (e.g., Cremophor ~ A and O, Brij ~ ), polyethyleneglycol esters of fatty acids (e.g., Cremophor ~ AP, Myrj ~ ), polyetheralcohols (e.g., Pluronic ~ ), etc.
Only amphiphilic substances which are capable of forming bilayers (i.e., double layers) in the aqueous phase can be used as bilayer-forming substances; that is, substances of polar (hydrophilic) as well as apolar (lipophilic) properties.
~8799 Suitable bilayer forming substances include, particularly, phospholipids, for instance phosphogly-cerides (diesters, monoesters, diethers, monoethers wherein the ester and ether groups preferably are of 8 to 24 carbon atoms each) such as lecithins (phospha-tidylcholines), kephalins (phosphatidyl-ethanolamines, phosphatidylserines), inositolphosphatides, phospha-tidylic acids, phosphatidylglycerols, cardiolipin;
sphingolipids, e.g., sphingomyelin; glycolipids, e.g., cerebrosides, gangliosides; furthermore, e.g., fatty acids of, preferably, 8 to 24 carbon atoms as well as their esters, salts and amides; alkyl ethers of, pre-ferably 8 to 24 carbon atoms; alkyl ether derivatives of, preferably, 8 to 24 carbon atoms, such as 1,3-propanediol-phospholipids; higher alkylamines of, preferably, 8 to 24 carbon atoms, e.g., stearyl amine;
fatty alcohols of preferably 8 to 24 carbon atoms, e.g., stearyl alcohol; higher alkylthiols of, preferably, 8 to 24 carbon atoms; etc. Furthermore, mixtures of these substances are also suitable. In general, the alkyl chains of the cited substances can be straight or branched.
The de-tergent and bilayer-forming substances form a ternary system with water, which is referred to here as a mixed micelle. The colloidal solution of the mixed micelle, which is subsequently called the micelle solution, can additionally contain electrolytes (pre-dominantly physiologically compatible inorganic salts ~1~8~99 such as sodium chloride sodium mono- and di-hydrogen-phosphate, potassium mono- and di-hydrogenphosphate, etc.), sorption promoters (such as organic solvents, fatty alcohols and fatty acid esters, etc.), auxiliaries (such as stabilizers and preservatives), peptides, proteins, nucleic acids, lipids, antigens and antibodies, and also active substances with biological and pharma-codynamic properties, etc. Suitable active substances include, for instance, medicinally active compounds such as sterols, e.g., cholesterol, sitosterol, etc.;
estrogens, e.g., estrone, estradiol and its esters, ethinylestradiol, etc.; gestagens, e.g., norethisterone aCetate~chlormadinone acetate, etc.; corticoids, e.g., hydrocortisone, prednisolone, prednisone, dexamethasone, betamethasone, etc. and their esters, e.g., hydro-cortisone acetate, betamethasone-17-valerate, etc.;
antibiotics, e.g.,-penicillins, cephalosporins, amino-glysides such as gentamicin, etc.; antimycotics and dermatics, such as clotrimazol, miconazol, dithranol, benzoyl peroxide, etc.; antiphlogistics such as indo-metacin, methyl, benzyl or 2-butoxyethyl nicotinate, etc.; etc. Furthermore, cosmetically active agents are suitable, e.g., light protecting agents or agents for the care of the skin.
The micelle solution can contain about 5 to 150, preferably 10 to 100 mg/ml of bilayer-forming substance and about 1 to 200, preferably 5 to 100 mg/ml of detergent.
.
Suitable concentrations of active substances and other mentioned micelle solution components may vary within broad limits; e.g., the active substances concentrations are usually 0.3 to 40, preferably 1 to 20 mg/ml. The concentration ranges for the other mentioned micelle solution components can also vary in these same ranges.
Suitably, the micelle solution is stirred, for example at about 75 rpm, in the interior space 4 of the dialysis cell by means of a magnetic stirring rod (which is not shown), in order to keep the detergent concentration virtually homogeneous.
Suitably, a dialysis liquid (the composition of which, generally, corresponas to that of the micelle solution except that the bilayer forming substance and the detergent are absent) is moved along the external sides of the membranes 1 in two flow-through compartments and with a sufficiently high velocity such that the detergent concentration in the dialysis liquid, which is built up by the detergent passing through the membranes, will remain below about 1% of the detergent concentration in the interior space ~ at virtually all points in this liquid and at all times ~or for all dialysis detergent concentrations of this invention), in parti-cular, including those where the liquid is in contact with the surfaces of the membranes 1 (= active membrane surfaces). In order to achieve this, it is advantageous to have a laminar flow of the dialysis liquid along the surfaces of the membranes 1. This laminar flow can be ~8~7~9 ensured by forming, in each of the side-wall elements 3, a meandering channel 5 through which the dialysis liquid must flow. The partitions 5a, between the mutually parallel sections of the channel, form flow-guiding elements for the dialysis liquid, which are in contact with the respective membrane 1. The dialysis liquid is introduced into the channel 5, at the bottom, through an inlet 6 in the side-wall element 3, and withdrawn from the channel 5, at the top, through an outlet 7. The average flow velocity in the channel 5 is advantageously between 20 and 600 cm/minute and preferably about 300 cm/minute, for a channel cross-section of, for example, about 1 r~m2 (width 2 mm, depth 0.5 mm).
Of course, it is also possible to use a spiral channel in place of the meandering channel 5. If desired, it is also possible to arrange several mutually parallel channels, separated from one another by partitions, between the inlet 6 and the outlet 7.
In certain cases, it is also possible to dispense with the carrying channel, i.e., to let the dialysis liquid flow on the external sides of the membranes through cylindrical flow-through compartments which are not interrupted by flow-guiding elements. In fact, in th s case, in particular if the flow-through compartments are relatively thick, measured normal to the membranes, the results (uniformity of the vesicle size) are some-what less good, but are still satisfactory, provided that it is ensured that the flow velocity of the dialysis liquid in the immediate vicinity of the membrane surface is in the region of 0.2 - 6 m/minute, preferably 1-3 m/minute, at virtually all points, and that there are virtually no regions with stagnating dialysis liquid, in which the detergent concentrations could become too high.
Thus, homogeneous bilayer vesicles of defined size, which, if appropriate, can contain auxiliaries, peptides, proteins, nucleic acids, lipids, antigens or antibodies, or also active substances with biological and pharmacodynamic properties, are obtained in the interior space 4 after a relatively short dialysis time, (e.g., 1 - 3 hours), in the form of an aqueouS
dispersion. Depending on their solubility properties, these additives are encapsulated inside the bilayer vesicles and/or incorporated in the double layer and/or taken up on the outside of the double layer, whereupon the bilayer vesicles can be used, for example, as carriers for biologically and/or pharmacodynamically active substances and/or themselves constitute pharmaceutical preparations.
The dispersion obtained contains about 5 to 150, preferably 10 to 100 mg/ml of the bilayer forming sub-stance and, if desired, up ~ 40, preferably up to 20 mg/ml of the active substance. If desired, an obtained dilute dispersion can also be concentrated, e.g., by partial evaporation or by partial lyophilization, suitably up to a concentration of about 150, preferably about 100 ~' 8'799 mg/ml of the bilayer forming substance only, however.
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative EXAMPLES OF A PREPARATION
65 mg of egg lecithin in ethanolic solution are evaporated to dryness and the residue is resuspended in 5 ml of a 1 mM phosphate buffer (composed of Na2HPO4 2H2O, KH2PO4 and 0.9~ NaCl) of pH 7.3 and ionic strength 0.16.
58.3 mg of solid sodium cholate are added to this suspension, while stirring constantly, and the mixture is left to stand for two minutes at room temperature under a n~trogen atmosphere, until the formation of the mixed micelles is complete ~the micelle solution becomes clear). To remove the sodium cholate, the micelle solution is subjected at room temperature, to the flow-through dialysis system described in Figures 1 and 2, the micelle solution being stirred constantly (75 rpm).
~B7~9 cellulose membranes with a molecular exclusion limit of about 10,000 are used as the dialysis membranes.
The flow rate of the dialysate is about 3 ml/minute in each side-wall element 3. Bilayer vesicles are obtained after a dialysis time of 20 - 24 hours, the residual cholate contents of which are less than 1%, relative to the initial cholate content. Bilayer vesicles pro-duced under these conditions are homogeneous and have a diameter of 60 ~ 3 nm. The comprehensive physico-chemical characterization of these vesicles is describedin Biochim. Biophys. Acta. 512, 147-155 (1978).
EXAMPLES 2 to 17 The size of the bilayer vesicles can be influ-enced, for example, by using dialysis membranes with different permeation properties, and/or by varying the bilayer-forming substances, and/or by varying the molar ratio of bilayer-forming substances/detergent, and/or by selection of detergent. Results are summarized in the following table.
a o ~ ~c ~L, E~ ~ o o O O O O C ~ 1 o o o o N O O O
~ _ l _ 1 ~ - _ __~
7~ h~L~olo` O O n ~ O O ~ O ~ w ~ I ~ O
~ ~ ~- tili-f~ ~; {~ 3 ~O~
- ~ I I I I I I I
~ C O O O O O 0 ~ CO ~~ ~ ~ ~ ,O I
~ ~ i I-~rl 11 11 11 11 ~
xo ~ ~ i~ ~ ~ 1- ~ o ~879~
The bilayer vesicles of defined size, produced in accordance with the process described, can be used as carriers for biologically and pharmacodynamically active substances and/or can be employed as a pharma-ceutical preparation. Pharmaceutical preparations canthus be produced in such a way that the bilayer vesicles are mixed as the active constituent, with a carrier suitable for therapeutic administration, and, if appropriate, the mixture is converted to a particular galenic form.
The following galenic forms of administration are possible:
ampoules, in particular sterile injection and infusion solutions, the colloidal solution of the bilayer vesicles containing pharmacodynamically active substances being subjected to an antimicrobial treatment;
solutions, in particular syrups, eye drops and nose drops, which can contain diverse auxiliaries in addition to the bilayer vesicle solution described above;
non-metering aerosols and metering aerosols, which can contain propellent gas and stabilizers in addition to the bilayer vesicle solution described above;
emulsions, such as water-in-oil or oil-in-water emulsions, ~or parenteral, oral and topical, (e.g., creams) administration, and also emulsions of these types which have been processed to give corresponding nonmetering aerosols or metering aerosols. Water-in-oil ' .
' 79~
emulsions form, for example, the contents of soft genatin capsules which can be administered perorally or rectally.
Furthermore, gels and the most recently developed therapeutic systems based on diffusion, osmotic and soluble units, such as, for example, those known by the trade marks OCUSERT and BIOLGRAVIPLAN, the displacement pump ALZET, and by the (oral therapeutic system, known by the name OROS, can also be used as possible forms of administration, which again comprise the colloidal solutions of the bilayer vesicles containing pharmacodynamically active substances.
Bilayer vesicles in the lyophilized state can be processed, together with corresponding pharmaceutical auxiliaries to give tablets or dragees.
Example of an application: hydrogel (a) In analogy to Example 1, 320 mg of egg lecithin, 80 mg of cholesterol and 40 mg of betamethasone 17~valerate are dissolved in ethanol. The solution is evaporated to dryness, the residue is resus-pended in 20 ml of phosphate buffer, and 400 mg of sodium cholate is added.
Thereafter, the procedure of Example 1 is followed.
(b) In 75 ml of water, there are dissolved 0.2 g of potassium sorbate, 0-224 g of Na2HPO4-12H2O and 0.64 g of K~12P04. With light warm-ing and vigorous stirring, 2 g of hydroxyethyl cellulose is dissolved in the solution obtained. After 0.5 hour of standing, `' ~ - 19 -~. :i ,i ~1~8799 2 g of glycerol is added with stirring, followed by the liposome dispersion obtained according to (a).
The volume of the mixture is adjusted to 100 ml by adding water.
The obtained hydrogel contains 0.04% of active substance and shows a pH value of 5.8 to 6.3.
The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
.
To avoid uncontrollable changes in the concen-tration gradient transverse to the semi-permeable membrane, the process of this invetnion comprises moving the dialysis liquid, on at least one side of a semi-permeable membrane, at a velocity such that the detergent concentration in the dialysis liquid, on virtually the whole of the active surface of the membrane, in any case on at least 90% of this surface, is at most 10% of the detergent concentration in the micelle solution in contact with the other side of the membrane, and maintaining a homogeneous detergent concentration ~1~8~9 in the micelle solution by the movement, e.g., stirring, of the latter.
In this way, by keeping the detergent concentration in the dialysis liquid which is in contact with the membrane as low as possible at all points, preferably below about 2%, for example at about 1% or less, relative to the detergent concentration in the micelle solution, it is possible to ensure that, at all points on the active membrane surface, virtually identical concentration gradients are formed normal to the membrane surface. Homogeneous bilayer vesicles of a defined size, which can be used as carriers for biologically and pharmacodynamically active substances and/or can be employed as pharmaceutical preparations, are thereby obtained after a relatively short dialysis time.
Preferably, the dialysis liquid is carried past the semi-permeable membrane, with a constant flow velocity in laminar flow, in such a way that a linear concentration ~radient of the detergent is formed from the entry of the dialysis liquid into the flow-through compartment up to its discharge as dialysate. In flow-through dialysis of this type, the intermediates resulting from the formation of the bilayer vesicles are already in themselves homogeneous and defined.
The desired homogeneous bilayer vesicles of defined size are formed from these intermediates after removal of the detergent. The bilayer vesicle size can be con-trolled and selected conventionally byselection of the molar ratio of bilayer-forming substances/detergent in the initially formed colloidal solution, or by suitable choice of the detergent, or by choice of the dialysis kinetics of the detergent. Such dialysis kinetics, (i.e., dialysis rate) in turn depend, in a known manner, on the temperature, the ratio of membrane surface area/solution volume, the type of membrane (thickness, pore size), the concentration and the physical and chemical properties of the substances to be dialyzed. (See, e.g., a) "Membrane Separation Processes", P. Meares ed., chapter 1 and 2, p. 1-79, Elsevier Scientific Publ. Comp., New York (1979); b) Biochemistry 18, 4173-4176 10 (1976).
A laminar flow of the dialysis liquid over the membrane surface has the advantage that the flow velocity can be kept approximately the same over the whole surface, and this is important since the flow velocity should be as high as possible, interalia because of the desired low deter-gent concentration in the dialysis liquid, but a certain maximum, beyond which the molecular film on the membrane would be destroyed, of course, should not be exceeded. Preferably, the flow velocity of the dialysis li-quid in the immediate vicinity of the membrane surface, at as many points as possible, is in the region of 0.2 - 6 m~minute, advantageously in the region of 1-3 m/minute.
The preferred laminar flow can be ensured, for example, by arranging, in the flow-through compartment, ., ~148799 guide elements which are in contact with the membrane and which carry the dialysis liquid along the surface of the membrane in laminar flow. For example, the dialysis liquid can be carried over the surface of the membrane in a meandering or spiral channel in an element which is in contact with the membrane. Alternatively, it is also possible simply to construct the flow-through compartment with very low thickness (measured normal to the membrane), preferably a thickness of less than 1 mm. If this thickness is not more than about 2 mm and the dialysis liquid is introduced into the flow-through compartment, distributed over the width of the latter, an approximately laminar flow is likewise achieved at virtually all points.
The movement of the micelle solution in contact with the other side of-the semi-permeable membrane, which movement is employed to rnaintain a homogeneous detergent concentration in the micelle solution, can be achieved, for example, by stirring with a mechanical stirring member (for example a magnetic stirring rod), or by forcing an inert gas into the chamber containing the micelle solution, or by moving the whole dialysis device to and fro (tilting movements) with this chamber.
The drawing shows a dialysis device with which anembodiment of the process of this invention can be carried out.
In the dialysis cell of Figures 1 and 2, two semi-permeable membranes 1 are arranged between the ring 2 ~8799 and, in each case, a side-wall element 3. A colloidal solution of mixed micelles is brought (e.g., through closable orifices in ring 2, which are not shown) into the interior space 4 between the two membranes 1.
The semi-permeable membranes must be impermeable to the bilayer-forming substances and to the aggregates or associates (e.g., the micelles, unilamellar or multi-lamellar vesicles) formed therefrom, but permeable to solvents and to auxiliaries and active substances dis-solved therein. The following are particularly suitable as components of the membranes: cellulose, hydrated cellulose, regenerated cellulose (e.g., cellophane) as well as cellùlose derivatives such as acetyl cellulose, furthermore polyamides, polyalkylenes such as polyethy-lene or polypropylene, polyesters, polyvinyl chloride,polytetrafluoroethylene, polycarbonates, etc.
The preferred membrane thickness is about 5 to about 20~m.
The mixed micelles are produced from a deter-gent (solubilizer) and bilayer-forming substances.
Suitable micelle-forming solubilizers are nonionic, anionic, cationic or amphoteric detergents.
The following are particularly suitable as detergents: cholic acid, their salts and derivatives such as desoxycholic acid, taurocholic acid, cheno-desoxycholic acid, lithocholic acid, glycocholic acid and their salts, preferably their sodium salts; glyco-sides, above all monomeric or oligomeric sugar derivatives 9s' with lipophilic sidechain,e.g., 1-O~n-hexyl-~-D-glucopyranoside, l-O-n-heptyl-~-D-glucopyranoside or l-O-n-octyl-~-D-glucopyranoside.
Among the anionic solubilizers, there are suited in particular the Na and K salts of fatty acids of, preferably, 8 to 24 C atoms, amine soaps (e.g., tri-ethanolamine stearate), salts of sulfuric and sulfonic acid esters of higher fatty alcohols such as sodium lauryl sulfate, docusate sodium salt or sodium lauryl sulfonate; among the cationic, quaternary ammonium compounds. Suitable nonionic solubilizers include, e.g., partial fatty acid esters of polyvalent alcohols such as glycerol monostearate, pentaerythritol mono-stearate; partial fatty acid esters of sorbitan (e.g., Span ~ , Crill ~ ) and of polyoxyethylene sorbitan (e.g., Tween ~ ), reaction products of castor oil or hydrogenated castor oil with ethylene oxide (e.g., Cremophor ~ EL), ethoxylated saturated fatty alcohols (e.g., Cremophor ~ A and O, Brij ~ ), polyethyleneglycol esters of fatty acids (e.g., Cremophor ~ AP, Myrj ~ ), polyetheralcohols (e.g., Pluronic ~ ), etc.
Only amphiphilic substances which are capable of forming bilayers (i.e., double layers) in the aqueous phase can be used as bilayer-forming substances; that is, substances of polar (hydrophilic) as well as apolar (lipophilic) properties.
~8799 Suitable bilayer forming substances include, particularly, phospholipids, for instance phosphogly-cerides (diesters, monoesters, diethers, monoethers wherein the ester and ether groups preferably are of 8 to 24 carbon atoms each) such as lecithins (phospha-tidylcholines), kephalins (phosphatidyl-ethanolamines, phosphatidylserines), inositolphosphatides, phospha-tidylic acids, phosphatidylglycerols, cardiolipin;
sphingolipids, e.g., sphingomyelin; glycolipids, e.g., cerebrosides, gangliosides; furthermore, e.g., fatty acids of, preferably, 8 to 24 carbon atoms as well as their esters, salts and amides; alkyl ethers of, pre-ferably 8 to 24 carbon atoms; alkyl ether derivatives of, preferably, 8 to 24 carbon atoms, such as 1,3-propanediol-phospholipids; higher alkylamines of, preferably, 8 to 24 carbon atoms, e.g., stearyl amine;
fatty alcohols of preferably 8 to 24 carbon atoms, e.g., stearyl alcohol; higher alkylthiols of, preferably, 8 to 24 carbon atoms; etc. Furthermore, mixtures of these substances are also suitable. In general, the alkyl chains of the cited substances can be straight or branched.
The de-tergent and bilayer-forming substances form a ternary system with water, which is referred to here as a mixed micelle. The colloidal solution of the mixed micelle, which is subsequently called the micelle solution, can additionally contain electrolytes (pre-dominantly physiologically compatible inorganic salts ~1~8~99 such as sodium chloride sodium mono- and di-hydrogen-phosphate, potassium mono- and di-hydrogenphosphate, etc.), sorption promoters (such as organic solvents, fatty alcohols and fatty acid esters, etc.), auxiliaries (such as stabilizers and preservatives), peptides, proteins, nucleic acids, lipids, antigens and antibodies, and also active substances with biological and pharma-codynamic properties, etc. Suitable active substances include, for instance, medicinally active compounds such as sterols, e.g., cholesterol, sitosterol, etc.;
estrogens, e.g., estrone, estradiol and its esters, ethinylestradiol, etc.; gestagens, e.g., norethisterone aCetate~chlormadinone acetate, etc.; corticoids, e.g., hydrocortisone, prednisolone, prednisone, dexamethasone, betamethasone, etc. and their esters, e.g., hydro-cortisone acetate, betamethasone-17-valerate, etc.;
antibiotics, e.g.,-penicillins, cephalosporins, amino-glysides such as gentamicin, etc.; antimycotics and dermatics, such as clotrimazol, miconazol, dithranol, benzoyl peroxide, etc.; antiphlogistics such as indo-metacin, methyl, benzyl or 2-butoxyethyl nicotinate, etc.; etc. Furthermore, cosmetically active agents are suitable, e.g., light protecting agents or agents for the care of the skin.
The micelle solution can contain about 5 to 150, preferably 10 to 100 mg/ml of bilayer-forming substance and about 1 to 200, preferably 5 to 100 mg/ml of detergent.
.
Suitable concentrations of active substances and other mentioned micelle solution components may vary within broad limits; e.g., the active substances concentrations are usually 0.3 to 40, preferably 1 to 20 mg/ml. The concentration ranges for the other mentioned micelle solution components can also vary in these same ranges.
Suitably, the micelle solution is stirred, for example at about 75 rpm, in the interior space 4 of the dialysis cell by means of a magnetic stirring rod (which is not shown), in order to keep the detergent concentration virtually homogeneous.
Suitably, a dialysis liquid (the composition of which, generally, corresponas to that of the micelle solution except that the bilayer forming substance and the detergent are absent) is moved along the external sides of the membranes 1 in two flow-through compartments and with a sufficiently high velocity such that the detergent concentration in the dialysis liquid, which is built up by the detergent passing through the membranes, will remain below about 1% of the detergent concentration in the interior space ~ at virtually all points in this liquid and at all times ~or for all dialysis detergent concentrations of this invention), in parti-cular, including those where the liquid is in contact with the surfaces of the membranes 1 (= active membrane surfaces). In order to achieve this, it is advantageous to have a laminar flow of the dialysis liquid along the surfaces of the membranes 1. This laminar flow can be ~8~7~9 ensured by forming, in each of the side-wall elements 3, a meandering channel 5 through which the dialysis liquid must flow. The partitions 5a, between the mutually parallel sections of the channel, form flow-guiding elements for the dialysis liquid, which are in contact with the respective membrane 1. The dialysis liquid is introduced into the channel 5, at the bottom, through an inlet 6 in the side-wall element 3, and withdrawn from the channel 5, at the top, through an outlet 7. The average flow velocity in the channel 5 is advantageously between 20 and 600 cm/minute and preferably about 300 cm/minute, for a channel cross-section of, for example, about 1 r~m2 (width 2 mm, depth 0.5 mm).
Of course, it is also possible to use a spiral channel in place of the meandering channel 5. If desired, it is also possible to arrange several mutually parallel channels, separated from one another by partitions, between the inlet 6 and the outlet 7.
In certain cases, it is also possible to dispense with the carrying channel, i.e., to let the dialysis liquid flow on the external sides of the membranes through cylindrical flow-through compartments which are not interrupted by flow-guiding elements. In fact, in th s case, in particular if the flow-through compartments are relatively thick, measured normal to the membranes, the results (uniformity of the vesicle size) are some-what less good, but are still satisfactory, provided that it is ensured that the flow velocity of the dialysis liquid in the immediate vicinity of the membrane surface is in the region of 0.2 - 6 m/minute, preferably 1-3 m/minute, at virtually all points, and that there are virtually no regions with stagnating dialysis liquid, in which the detergent concentrations could become too high.
Thus, homogeneous bilayer vesicles of defined size, which, if appropriate, can contain auxiliaries, peptides, proteins, nucleic acids, lipids, antigens or antibodies, or also active substances with biological and pharmacodynamic properties, are obtained in the interior space 4 after a relatively short dialysis time, (e.g., 1 - 3 hours), in the form of an aqueouS
dispersion. Depending on their solubility properties, these additives are encapsulated inside the bilayer vesicles and/or incorporated in the double layer and/or taken up on the outside of the double layer, whereupon the bilayer vesicles can be used, for example, as carriers for biologically and/or pharmacodynamically active substances and/or themselves constitute pharmaceutical preparations.
The dispersion obtained contains about 5 to 150, preferably 10 to 100 mg/ml of the bilayer forming sub-stance and, if desired, up ~ 40, preferably up to 20 mg/ml of the active substance. If desired, an obtained dilute dispersion can also be concentrated, e.g., by partial evaporation or by partial lyophilization, suitably up to a concentration of about 150, preferably about 100 ~' 8'799 mg/ml of the bilayer forming substance only, however.
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative EXAMPLES OF A PREPARATION
65 mg of egg lecithin in ethanolic solution are evaporated to dryness and the residue is resuspended in 5 ml of a 1 mM phosphate buffer (composed of Na2HPO4 2H2O, KH2PO4 and 0.9~ NaCl) of pH 7.3 and ionic strength 0.16.
58.3 mg of solid sodium cholate are added to this suspension, while stirring constantly, and the mixture is left to stand for two minutes at room temperature under a n~trogen atmosphere, until the formation of the mixed micelles is complete ~the micelle solution becomes clear). To remove the sodium cholate, the micelle solution is subjected at room temperature, to the flow-through dialysis system described in Figures 1 and 2, the micelle solution being stirred constantly (75 rpm).
~B7~9 cellulose membranes with a molecular exclusion limit of about 10,000 are used as the dialysis membranes.
The flow rate of the dialysate is about 3 ml/minute in each side-wall element 3. Bilayer vesicles are obtained after a dialysis time of 20 - 24 hours, the residual cholate contents of which are less than 1%, relative to the initial cholate content. Bilayer vesicles pro-duced under these conditions are homogeneous and have a diameter of 60 ~ 3 nm. The comprehensive physico-chemical characterization of these vesicles is describedin Biochim. Biophys. Acta. 512, 147-155 (1978).
EXAMPLES 2 to 17 The size of the bilayer vesicles can be influ-enced, for example, by using dialysis membranes with different permeation properties, and/or by varying the bilayer-forming substances, and/or by varying the molar ratio of bilayer-forming substances/detergent, and/or by selection of detergent. Results are summarized in the following table.
a o ~ ~c ~L, E~ ~ o o O O O O C ~ 1 o o o o N O O O
~ _ l _ 1 ~ - _ __~
7~ h~L~olo` O O n ~ O O ~ O ~ w ~ I ~ O
~ ~ ~- tili-f~ ~; {~ 3 ~O~
- ~ I I I I I I I
~ C O O O O O 0 ~ CO ~~ ~ ~ ~ ,O I
~ ~ i I-~rl 11 11 11 11 ~
xo ~ ~ i~ ~ ~ 1- ~ o ~879~
The bilayer vesicles of defined size, produced in accordance with the process described, can be used as carriers for biologically and pharmacodynamically active substances and/or can be employed as a pharma-ceutical preparation. Pharmaceutical preparations canthus be produced in such a way that the bilayer vesicles are mixed as the active constituent, with a carrier suitable for therapeutic administration, and, if appropriate, the mixture is converted to a particular galenic form.
The following galenic forms of administration are possible:
ampoules, in particular sterile injection and infusion solutions, the colloidal solution of the bilayer vesicles containing pharmacodynamically active substances being subjected to an antimicrobial treatment;
solutions, in particular syrups, eye drops and nose drops, which can contain diverse auxiliaries in addition to the bilayer vesicle solution described above;
non-metering aerosols and metering aerosols, which can contain propellent gas and stabilizers in addition to the bilayer vesicle solution described above;
emulsions, such as water-in-oil or oil-in-water emulsions, ~or parenteral, oral and topical, (e.g., creams) administration, and also emulsions of these types which have been processed to give corresponding nonmetering aerosols or metering aerosols. Water-in-oil ' .
' 79~
emulsions form, for example, the contents of soft genatin capsules which can be administered perorally or rectally.
Furthermore, gels and the most recently developed therapeutic systems based on diffusion, osmotic and soluble units, such as, for example, those known by the trade marks OCUSERT and BIOLGRAVIPLAN, the displacement pump ALZET, and by the (oral therapeutic system, known by the name OROS, can also be used as possible forms of administration, which again comprise the colloidal solutions of the bilayer vesicles containing pharmacodynamically active substances.
Bilayer vesicles in the lyophilized state can be processed, together with corresponding pharmaceutical auxiliaries to give tablets or dragees.
Example of an application: hydrogel (a) In analogy to Example 1, 320 mg of egg lecithin, 80 mg of cholesterol and 40 mg of betamethasone 17~valerate are dissolved in ethanol. The solution is evaporated to dryness, the residue is resus-pended in 20 ml of phosphate buffer, and 400 mg of sodium cholate is added.
Thereafter, the procedure of Example 1 is followed.
(b) In 75 ml of water, there are dissolved 0.2 g of potassium sorbate, 0-224 g of Na2HPO4-12H2O and 0.64 g of K~12P04. With light warm-ing and vigorous stirring, 2 g of hydroxyethyl cellulose is dissolved in the solution obtained. After 0.5 hour of standing, `' ~ - 19 -~. :i ,i ~1~8799 2 g of glycerol is added with stirring, followed by the liposome dispersion obtained according to (a).
The volume of the mixture is adjusted to 100 ml by adding water.
The obtained hydrogel contains 0.04% of active substance and shows a pH value of 5.8 to 6.3.
The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
.
Claims (11)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A process for producing bilayer vesicles from a colloidal solution comprising mixed micelles of a bilayer-forming substance and a detergent, the process comprising: removing the detergent from the micelle-containing colloidal solution by means of flow-through dialysis, the col-loidal solution being dialyzed against a dialysis liquid in a chamber whose walls are at least partially formed by a semi-permeable membrane, by moving the dialysis liquid along the outer side of the semi-permeable membrane at a velocity such that the detergent concentration in the dialysis liquid, on at least 90% of the active surface of the membrane, is at most 10% of the detergent concentration in the micelle solution in contact with the other side of the membrane, and by maintaining a homogeneous detergent concentration in the micelle solution by the movement of the latter.
2. A process of Claim 1, wherein the velocity of said dialysis liquid is chosen such that said detergent concentration in said dialysis liquid is at most 2% of the detergent concentration in the micelle solu-tion.
3. A process of Claim l, wherein the velocity of said dialysis liquid is chosen such that said detergent concentration in said dialysis liquid is at most 1% of the detergent concentration in the micelle solu-tion.
4. A process of Claim 1, wherein said dialysis liquid is carried along the membrane in at least one channel which is in contact with the outer side of the membrane.
5. A process of Claim 4, wherein said channel is a meandering channel.
6. A process of Claim 4, wherein said channel is a spiral channel.
7. A process of Claim 1, wherein said dialysis liquid is moved along the membrane in laminar flow.
8. A process of Claim 1, wherein said colloidal solution of said mixed micelles further comprises at least one of the following additives:
an electrolyte, a sorption promoter, an auxiliary, a peptide, a protein, a nucleic acid, a lipid, an antigen, an antibody or a biologically or pharmacodynamically active material.
an electrolyte, a sorption promoter, an auxiliary, a peptide, a protein, a nucleic acid, a lipid, an antigen, an antibody or a biologically or pharmacodynamically active material.
9. Bilayer vesicles produced by the process of Claim 1.
10. Bilayer vesicles of Claim 9, the bilayer forming material of which is lecithin.
11. Bilayer vesicles of Claim 9, comprising a biologically or pharmacodynamically active material.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA000368757A CA1148799A (en) | 1981-01-19 | 1981-01-19 | Dialysis process for the production of bilayer vesicles |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA000368757A CA1148799A (en) | 1981-01-19 | 1981-01-19 | Dialysis process for the production of bilayer vesicles |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1148799A true CA1148799A (en) | 1983-06-28 |
Family
ID=4118947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000368757A Expired CA1148799A (en) | 1981-01-19 | 1981-01-19 | Dialysis process for the production of bilayer vesicles |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA1148799A (en) |
-
1981
- 1981-01-19 CA CA000368757A patent/CA1148799A/en not_active Expired
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4438052A (en) | Process and device for producing bilayer vesicles | |
US4731210A (en) | Process for the preparation of liposomal medicaments | |
Zumbuehl et al. | Liposomes of controllable size in the range of 40 to 180 nm by defined dialysis of lipid/detergent mixed micelles | |
Rigaud et al. | Reconstitution of membrane proteins into liposomes: application to energy-transducing membrane proteins | |
CA1289072C (en) | Scaled-up production of liposome-encapsulated hemoglobin | |
US4917951A (en) | Lipid vesicles formed of surfactants and steroids | |
US5049392A (en) | Osmotically dependent vesicles | |
US4911929A (en) | Blood substitute comprising liposome-encapsulated hemoglobin | |
Weiner et al. | Liposomes as a drug delivery system | |
US5567434A (en) | Preparation of liposome and lipid complex compositions | |
US5277914A (en) | Preparation of liposome and lipid complex compositions | |
US5593687A (en) | Aqueous dispersion containing liposomes | |
Li et al. | A novel method for the preparation of liposomes: freeze drying of monophase solutions | |
KR0137783B1 (en) | Method for making liposomes of enhanced entrapping capacity toward foreign substances to be encapsulated | |
EP0460720B1 (en) | A method of extruding liposomes | |
EP0731690B1 (en) | Liposomes with enhanced entrapment capacity, production and use thereof | |
EP0292403B1 (en) | Prostaglandin-lipid formulations | |
EP0349579B1 (en) | Lipid vesicles formed of surfactants and steroids | |
US5185154A (en) | Method for instant preparation of a drug containing large unilamellar vesicles | |
US6241967B1 (en) | Process and device for the production of liquid, disperse systems | |
NZ225510A (en) | Large unilamellar vesicles and delivery systems using them | |
CA1148799A (en) | Dialysis process for the production of bilayer vesicles | |
Andrieux et al. | Insertion and partition of sodium taurocholate into egg phosphatidylcholine vesicles | |
EP0357773B1 (en) | Process for preparing liposomes | |
Gao et al. | Solid core liposomes with encapsulated colloidal gold particles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |